{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:00:52Z","timestamp":1790006452498,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.clinthera.2018.05.011","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T14:51:01Z","timestamp":1532357461000},"page":"1214-1222.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Preventive Effects of Renin-angiotensin System Inhibitors on Oxaliplatin-induced Peripheral Neuropathy: A Retrospective Observational Study"],"prefix":"10.1016","volume":"40","author":[{"given":"Mami","family":"Uchida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1591-4051","authenticated-orcid":false,"given":"Hitoshi","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5498-0564","authenticated-orcid":false,"given":"Shingo","family":"Takatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Namba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-9869","authenticated-orcid":false,"given":"Ryuji","family":"Uozumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromu","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2018.05.011_bib0001","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","article-title":"Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer","volume":"26","author":"Cassidy","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0002","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0003","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S1470-2045(13)70490-X","article-title":"Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial","volume":"14","author":"Yamada","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0004","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/annonc\/mdu472","article-title":"Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer","volume":"26","author":"Yamada","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0006","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","article-title":"Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial","volume":"15","author":"Noh","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0007","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0008","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont A,","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0009","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0010","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0011","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1200\/JCO.2013.52.0536","article-title":"Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB\/Alliance)","volume":"32","author":"Loprinzi","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0012","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10147-015-0784-9","article-title":"Preventive Effect of Goshajinkigan on Peripheral Neurotoxicity of FOLFOX Therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study","volume":"20","author":"Oki","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0013","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2017-0235","article-title":"Pregabalin for the prevention of oxaliplatin-induced painful neuropathy: a randomized, double-blind trial","volume":"22","author":"de Andrade","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0014","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00520-015-2876-5","article-title":"MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy","volume":"24","author":"Zimmerman","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0015","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4103\/2008-7802.169021","article-title":"Effect of Vitamin E on oxaliplatin-induced peripheral neuropathy prevention: a randomized controlled trial","volume":"6","author":"Salehi","year":"2015","journal-title":"Int J Prev Med"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0016","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/139740","article-title":"Efficacy of Goshajinkigan for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients","volume":"2013","author":"Yoshida","year":"2013","journal-title":"J Oncol"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0017","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.neuroscience.2007.09.026","article-title":"Angiotensin II type 2 receptors facilitate reinnervation of phenol-lesioned vascular calcitonin gene-related peptide-containing nerves in rat mesenteric arteries","volume":"150","author":"Hobara","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0018","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1291\/hypres.29.361","article-title":"Chronic hyperinsulinemia enhances adrenergic vasoconstriction and decreases calcitonin gene-related peptide-containing nerve-mediated vasodilation in pithed rats","volume":"29","author":"Takatori","year":"2006","journal-title":"Hypertens Res"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0019","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/hr.2011.97","article-title":"Hyperinsulinemia induces hypertension associated with neurogenic vascular dysfunction resulting from abnormal perivascular innervations in rat mesenteric resistance arteries","volume":"34","author":"Zamami","year":"2011","journal-title":"Hypertens Res"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0020","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2337\/db11-1468","article-title":"Candesartan cilexetil improves angiotensin II type 2 receptor-mediated neurite outgrowth via the PI3K-Akt pathway in fructose-induced insulin-resistant rats","volume":"61","author":"Hashikawa-Hobara","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0021","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ctrv.2008.01.003","article-title":"A review on oxaliplatin-induced peripheral nerve damage","volume":"34","author":"Argyriou","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0022","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10147-011-0298-z","article-title":"Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer","volume":"17","author":"Inoue","year":"2012","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0023","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0021-9681(82)90058-3","article-title":"Adjusted survival curve estimation using covariates","volume":"35","author":"Makuch","year":"1982","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0024","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s00520-014-2242-z","article-title":"A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration","volume":"22","author":"Beijers","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fphar.2017.00086","article-title":"Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review","volume":"8","author":"Kerckhove","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2018.05.011_bib0026","doi-asserted-by":"crossref","first-page":"5614","DOI":"10.1002\/cncr.27593","article-title":"Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01","volume":"118","author":"Kidwell","year":"2012","journal-title":"Cancer"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818302388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818302388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T23:19:10Z","timestamp":1535584750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291818302388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0149291818302388"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.05.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preventive Effects of Renin-angiotensin System Inhibitors on Oxaliplatin-induced Peripheral Neuropathy: A Retrospective Observational Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}